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Abstract: 
Sodium hyaluronate (HYA) warrants attention as a material for inhalation due to its (i) 
therapeutic potential, (ii) utility as a formulation excipient or drug carrier, and (iii) ability to 
target lung inflammation and cancer. This study aimed to overcome formulation and 
manufacturing impediments to engineer biocompatible spray-dried HYA powders for 
inhalation. 
Novel methodology was developed to produce HYA microparticles by spray drying. Different 
types of surfactant were included in the formulation to improve powder respirability, which 
was evaluated in vitro using cascade impactors.  The individual formulation components and 
formulated products were evaluated for their biocompatibility with A549 respiratory epithelial 
cells. 
The inclusion of stearyl surfactants, 5% w/v, produced the most respirable HYA-powders; 
FPF 59.0-66.3%. A trend to marginally higher respirability was observed for powders 
containing stearylamine > stearyl alcohol > cetostearyl alcohol. Pure HYA was biocompatible 
with A549 cells at all concentrations measured, but the biocompatibility of the stearyl 
surfactants (based on lethal concentration 50%; LC50) in the MTT assay ranked stearyl 
alcohol > cetostearyl alcohol > stearylamine with LC50 of 24.7, 13.2 and 1.8 µg/mL, 
respectively. 
We report the first respirable HYA powders produced by spray-drying. A lead formulation 
containing 5% stearyl alcohol was identified for further studies aimed at translating the 
proposed benefits of inhaled HYA into safe and clinically effective HYA products.  
 
Key words:  Hyaluronic acid, hyaluronan, inhalation toxicology, dry powder inhaler, 
particle engineering 
 
 
 
1. Introduction 
Sodium hyaluronate (HYA) warrants attention as a product for inhalation on account of (i) 
having inherent therapeutic potential, (ii) offering utility as a formulation excipient or drug 
carrier, and (iii) possessing targeting potential for disease sites in the lungs, e.g. macrophages 
or lung cancer (Liao et al., 2008).  The development of inhaled formulations has been limited 
by difficulty in formulating and manufacturing sodium hyaluronate as a powder for 
inhalation, therefore this study aimed to engineer a flowable, highly respirable powder. 
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Hyaluronate is an endogenous glycosaminoglycan present in matrices such as the 
extracellular matrix and synovial fluid. It is a linear polysaccharide composed of a repeating 
disaccharide unit of N-acetyl-D-glucosamine and D-glucuronic acid bound by β 1,4 
glycosidic bond. The disaccharides are linked by β 1,3 bonds to form the hyaluronic acid 
chains (Lapcík L Jr and et al., 1998). In vivo, hyaluronate exists as a polyanion rather than its 
protonated form, hyaluronic acid, although the terms are often used synonymously in the 
literature (Liao et al., 2008).  The use of high molecular weight sodium hyaluronate is 
approved in several pharmaceutical products for topical application and injection and as a 
functional component of some nebuliser solutions.  Hence, hyaluronate is considered to be a 
biocompatible, biodegradable and non-immunogenic biomaterial.   
In the lungs, the physiological function of hyaluronate is to stabilize connective tissue, 
organize extracellular matrix, control hydration / water homeostasis (Gerdin and Hällgren, 
1997), as well as modulating cell migration and phagocytosis (Turino and Cantor, 2003).  In 
disease hyaluronate plays a role in the inflammatory response (Cantor, 2007), tissue 
remodeling (Petrigni and Allegra, 2006) and various CD44 receptor-mediated functions in 
cell detachment, carcinogenesis and inflammation (Zhong et al., 2016). The CD44 receptor 
belongs to the family of cell adhesion molecules specifically involved in the control of cell 
behaviour by mediating contact between cells or between cells and the extracellular matrix, 
which is essential for maintaining tissue integrity (Arpicco et al., 2013). However, these 
important functions are also central to pathological conditions including tumour progression 
and metastasis (Orian-Rousseau, 2010). CD44 receptors bind high molecular weight 
hyaluronate, but can also interact with shorter chains (Tammi et al., 2002). 
Several studies have reported hyaluronate to be a potential therapeutic agent for inflammatory 
lung disorders, in particular for prevention of exercise-induced bronchoconstriction in asthma, 
emphysema and COPD (Petrigni and Allegra, 2006; Souza-Fernandes et al., 2006). Different 
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mechanisms of actions linked to the inhibition of lung elastase, binding to elastic fibers and 
limitation of cell-cytokine interactions via CD44 receptor have been described (Cantor et al., 
2011; Iskandar et al., 2009). HYA is an active component of two inhalation products.  Yabro® 
(Ibsa Farmaceutici, IT) is a high viscosity hyaluronate solution for nebulization (MW 800-
1000 kDa, 0.3% w/v) to reduce bronchial reactivity induced by inhalation of 
allergens/pollutants or by physical effort (Gelardi et al., 2013). In this formulation, HYA 
improves palatability and reduces potential side effects of nebuliser solutions such as irritation 
and cough.  Hyaluronate (MW 500 kDa, 0.1 % w/v) is also available in a hypertonic solution 
of NaCl at 7% (Hyaneb®, Chiesi Farmaceutici, IT) which decreases mucus viscosity in cystic 
fibrosis patients by attracting water to hydrate the mucus (Nenna et al., 2011). Hyaluronate 
has also been proposed as carrier for drug delivery to the lung, either as a scaffold for 
modified release formulations or for particle/drug targeting to alveolar macrophages, e.g. for 
treatment of tuberculosis (Hwang et al., 2008).  
Despite this potential, HYA has not been developed as a powder formulation for lung 
delivery, either alone or in combination with drugs.  HYA particles have poor flowability and 
tend to be cohesive requiring the use an adhesive mixture with lactose in order to be 
aerosolized (Hwang et al., 2008).  The aim of the present work was to investigate the use of 
different excipients to produce flowable, highly respirable and safe hyaluronate dry powders 
through a particle engineering approach based on spray drying.  Powder respirability was 
investigated in vitro and prototype formulations were evaluated for alveolar cell compatibility 
in vitro. 
 
2 Materials and methods 
2.1 Materials 
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Sodium hyaluronate (HYA; PrymalHyal 50, average MW=29504 Da) was purchased from 
Soliance (Pomacle, France). Stearylamine, L-lysine and thiazolyl blue tetrazolium bromide 
(MTT), sodium dodecyl sulphate (SDS), N,N-Dimethylformamide (DMF), RPMI-1640, Fetal 
Bovine Serum (FBS), L-glutamine, gentamicin were supplied by Sigma–Aldrich (Sigma 
Chemical Co., Milan, Italy). Stearyl alcohol, cetostearyl alcohol and stearylamine were 
purchased from ACEF Srl (Fiorenzuola d’Arda, IT). A single dose dry powder inhaler, RS01 
(Plastiape Spa, LC, IT), was used to aerosolize HYA powders for aerodynamic performance 
testing. Powder formulations were loaded in size 3 hypromellose capsules (Qualicaps Europe, 
Madrid, ES). All chemicals used were of analytical grade and water was purified (0.055 
µS/cm, TOC 1ppb) with Purelab pulse + Flex ultra-pure water (Elga Veolia, Milan, IT). A549 
alveolar epithelial cells were obtained from the American Type Cell Culture; tissue culture 
flasks (75 cm2 with ventilated caps) and 96-well plates were from Costar (Fisher Scientific, 
Loughborough, UK). Phosphate buffered saline (PBS) tablets were purchased from Oxoid Ltd 
(Basingstoke, UK). 
2.2 HPLC analysis of sodium hyaluronate (HYA) 
The content of HYA in every sample was determined by size exclusion – high performance 
liquid chromatography (SEC-HPLC) using a BioSep-SEC-s4000, 5 µm 7.8x100 mm column 
(Phenomenex Srl, Bologna, IT). Standard and samples were prepared in purified water. 
Mobile phase was prepared by dissolving 6.80 g of KH2PO4 in 1 L of purified water and the 
pH was adjusted to 7.0 with 5 M potassium hydroxide. The injection volume was set at 100 
µL, flow rate of the mobile phase was 1.0 mL/min and wavelength of detection was 200 nm. 
Linearity of response was tested before each analysis in the concentration range between 5 
and 500 µg/mL (R2 = 0.999). 
2.3 Production of HYA powders by spray drying 
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HYA powders were manufactured by spray-drying using a mini spray-dryer B-290 (BÜCHI 
Labortechnik AG, Flawil, Switzerland).  HYA was dissolved in purified water at room 
temperature and this solution was added to ethanol (water:ethanol ratio 30:70 v/v) under 
magnetic stirring at 50 rpm.  When excipients were incorporated in the formulation, they were 
added to the water or ethanol phase (according to excipient solubility). The compositions of 
hyaluronate formulations are reported in Tables 1 and 2. 
The solutions were spray-dried using the following process parameters: inlet temperature 90 
°C, drying air flow rate 750 L/h, solution feed rate of 3.0 mL/min and nozzle diameter of 0.7 
mm. Under these conditions an outlet temperature ranging from 45 to 52 °C was measured. A 
dehumidifier B-296 was used to control the air humidity of the system. Spray-dried powders 
were kept in the collector for at least 24 hours before use in order to reduce electrostatic 
charges. 
2.4 Particle size distribution  
The particle size distribution of the powders was measured using a laser light diffractometer 
Spraytec (Malvern Instruments Ltd, Worcestershire, UK) equipped with a 300 mm focal lens, 
which measures particle size in the range 0.1 to 900 µm. Samples were prepared by 
suspending 10 mg of the spray-dried powder in 10 mL of a solution of Span 85 (0.1 % w/v) in 
cyclohexane; the suspension was sonicated for 10 min to achieve complete particle 
dispersion. Particle size distribution was measured in triplicate with an obscuration threshold 
of 8%. Data were expressed as volume diameter of 10th (Dv10), 50th (Dv50) and 90th (Dv90) 
percentile of the particle population and as span value (Dv90-Dv10)/Dv50. 
2.5 Scanning Electron Microscopy 
Scanning electron microscopy (SUPRA 40, Carl Zeiss NTS GmbH, Oberkochen, Germany) 
was employed to investigate particle morphology and surface characteristics of the powders 
produced by spray-drying. The microscope was operated under high vacuum conditions with 
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1.5 kV accelerating voltage, at different magnifications. Powders were deposited on adhesive 
black carbon tabs pre-mounted on aluminium stubs and imaged without any metallization 
process. 
2.6 Thermo gravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA/DSC1 STARe System, Mettler Toledo, USA) was carried 
out on powder samples placed in 70 µL alumina pans with a pierced cover. Samples were 
heated under a flux of dry nitrogen (100 mL min-1) at 10 K min-1 in the 30-150 °C 
temperature range. 
2.7 Differential Scanning Calorimetry (DSC) 
 DSC measurements were performed on an Indium calibrated (onset of melting Tm = 157.1 
°C, enthalpy of melting ΔHm = -27.84 J g-1) Mettler DSC 821e (Mettler Toledo, USA) driven 
by STARe software (Mettler Toledo). DSC traces were recorded by placing precisely 
weighed quantities (6-9 mg) in a sealed and pierced 40 µL aluminium pan. Scans were 
performed between 25 to 150 °C at 10 K min-1 under a flux of dry nitrogen (100 mL min-1). 
Each powder sample was analysed at least in duplicate. Data relevant to the observed thermal 
events were reported as peak temperatures  
2.8 Aerodynamic performance 
A fast screening impactor (FSI, Copley Scientific Ltd, Nottingham, UK) was used as an 
abbreviated impactor to assess the aerodynamic performance of HYA powders. FSI is 
constituted of a Coarse Fraction Collector (CFC) that captures particles with an aerodynamic 
diameter larger than 5 µm and a Fine Fraction Collector (FFC) that collects particles with an 
aerodynamic diameter smaller than 5 µm. The respirable fraction was calculated as the ratio 
between the amount of powder collected in the FFC and the loaded dose.  The distribution of 
hyaluronate particles in the FSI was quantified by HPLC.  The entire system was connected to 
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a vacuum pump mod. 1000 (Erweka GmbH, Germany) which created the air flow rate to 
aerosolise the powder and distribute it in the FSI. 
HYA powders (5 mg) were loaded manually into a size 3 hypromellose capsule and 
aerosolized using a RS01 powder inhaler device. A single capsule was discharged inside the 
impactor for each test. The flow rate used during each test was adjusted, according to current 
USP monograph, with a Critical Flow Controller TPK (Copley Scientific, Nottingham, UK) 
in order to produce a pressure drop of 4 kPa over the inhaler. Thus, a flow rate of 60 L/min 
was set before each experiment by a Flow Meter DFM 2000 (Copley Scientific, Nottingham, 
UK). RS01 was activated and the vacuum applied for 4 seconds so that a volume of 4 L of air 
was drawn through the inhaler during the experiment. 
Andersen cascade impactor (ACI, Copley Scientific Ltd, Nottingham, UK) was employed in 
order to characterize in greater detail the aerodynamic behavior of the stearyl- surfactant 
formulations.  The ACI was assembled for use at flow rate of 60 L/min. Plates of each stage 
of the impactor were coated with a 1% w/v Span 85 solution in cyclohexane to prevent 
particles bouncing during the particle deposition. A dose of 5 mg of powder was loaded in a 
hypromellose capsule and aerosolized using an RS01 device as described above. In vitro 
deposition experiments were performed in triplicate. 
The measurement of the HYA deposited in the impactor allowed the calculation of deposition 
parameters: the delivered dose (DD) was the amount of HYA ex-device measured from the 
induction port (IP) to the filter (F). The fine particle dose (FPD) was the mass of HYA with 
aerodynamic diameter lower than 5 µm; the fine particle fraction (FPF) was the ratio between 
FPD and DD. The mass median aerodynamic diameter (MMAD) was determined by plotting 
the cumulative percentage of mass less than the stated aerodynamic diameter (probability 
scale) versus aerodynamic diameter (log scale). 
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2.9 Biocompatibility with A549 alveolar epithelial cells 
The A549 cell lines were obtained from the American Type Cell Culture and used between 
passages 90-110 to perform all biocompatibility experiments. Cells were grown in 75 cm2 
flasks (Costar Corning, UK) in a humidified 5% CO2/95% atmospheric air incubator at 37 °C. 
RPMI-1640 medium supplemented with 10% v/v foetal bovine serum (FBS), 1% v/v L-
glutamine and 0.1% v/v gentamycin was used as cell culture medium (CCM). 
Cell viability was measured by a reduction in metabolic activity measured using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For the MTT assay, 
cells were detached using trypsin-EDTA 0.25%:0.02% once they reached 80-85% of 
confluence and seeded in 96-well plates at a density of 10,000 cells per well (in 200 µL 
CCM).  The cells were incubated for 24 h to allow the cells to attach and form a monolayer. 
Prior to cytotoxicity test, the CCM was removed, replaced with 100 µL of fresh CCM 
containing the test concentrations of the stearyl surfactants, individually and in the 
formulations with HYA. 
Biocompatibility of the individual components (HYA, stearylamine, cetostearyl and stearyl 
alcohol) and the spray dried powders (HYA:surfactant  90:10) was evaluated over 24 h.  The 
test powders were dissolved in a medium:ethanol mixture (95:5) and incubated at 37°C for 1 
h before addition to the cells. All materials were tested over 9 different concentrations 
following a serial quarter log dilution and a CCM:ethanol (95:5) mixture was used as a 
negative control. 
After 24 h, cells were washed with PBS and 200 µL of fresh CCM was added. Finally, 50 µL 
of MTT solution (2.5 mg/mL in PBS) were added to each well and the plate was incubated for 
4 h in a humidified incubator, after which the solution was discarded.  The cells were lysed 
and formazan crystals formed were solubilised with 100 µL of a solution of 10% SDS in 
DMF:water (1:1). Cells were incubated with lysis solution overnight at 37°C before the 
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absorbance of solubilised formazan was measured at 570 nm using a SpectraMax microplate 
reader (Molecular Devices, UK). The cell viability was expressed as a percentage of negative 
control (100% metabolic activity). Lethal concentration 50% (LC50) values were calculated as 
the concentration that caused 50% reduction in MTT conversion from the sigmoidal 
relationship obtained by plotting log10 concentration of surfactant vs % cellular viability using 
GraphPad Prism (GraphPad Software, US). 
2.10 Statistical analysis 
The statistical analysis was performed with Microsoft Office Excel 15.1 (Microsoft Corp.) 
employing a two-tailed unpaired t-test with significance level fixed at p-value = 0.05. 
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3. Results  
3.1 Spray dried sodium hyaluronate powders with respirable attributes 
Hyaluronate powders from aqueous solutions of sodium hyaluronate could not be produced 
by spray drying since powder formed in the cyclone of the spray drier and the yield was only 
around 10%.  In order to accelerate the particle formation during the spray drying process, 
ethanol (70% v/v) was added to the aqueous solution of sodium hyaluronate. In this way, an 
adequate yield (68% by weight) was obtained, starting from solutions with 0.83-0.92% 
hyaluronate content (Table 1). The hyaluronate content of the powder was around 90%, and 
water content determined by TGA around 10%, thus affording a correct mass balance. The 
particle size distribution showed that this powder had a promising geometrical size (dv50 2.09) 
and a narrow distribution around the median value as indicated by a span of 0.45 (Figure 1A). 
However, the spray-dried hyaluronate powder was cohesive and characterised by the presence 
of many visible agglomerates.  When aerosolized using RS01 device into a fast screening 
impactor, 50% of the dose was retained inside the capsule, the capsule chamber and 
mouthpiece, indicating poor flowability (see Figure 1B) as a consequence of HYA 
microparticle cohesion.  The emitted dose did not de-aggregate completely leading to a low 
respirable fraction of 25%. 
It was hypothesized that the high cohesiveness was due to the strong negative surface charge 
of the sodium hyaluronate. It is known that electrostatic charge is one of five mechanisms that 
govern the deposition of inhaled particles in the lungs (Karner and Urbanetz, 2011; Wong et 
al., 2015). Furthermore, the electrostatic charge of the plastic constituting the dry powder 
inhaler devices can have a strong impact on material loss during manufacturing of the product 
and upon actuation of the inhaler (Karner and Urbanetz, 2011). 
Charged particles tend to adhere on the walls of the mixing vessel In the mixing process as 
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well as to the inhaler material during loading and discharging and thus influence the released 
dose (Karner and Urbanetz, 2011; Wong et al., 2015).  
Selected excipients, known fort they lubricant properties (Pamunuwa et al., 2016), were 
screened for their ability to enhance flow (evaluated as emitted dose) and reduce particle 
cohesiveness of the spray-dried powders (measured as higher respirable dose). The putative 
charge-modifying agents could be either a neutral molecule, such as mannitol, or a positively 
charge excipients, such as L-lysine or stearylamine, chosen to neutralize the negative charge 
of hyaluronate. The effect of these surfactants on powder characteristics was assessed by 
adding them at fixed concentration (10% w/w) to the hyaluronate solution before spray 
drying. 
The three hyaluronate:excipient solutions were spray dried and the powders characterized (see 
Table 2).  The yield of the production process was in all the case higher than 49%. The 
hyaluronate content was around 80% w/v, in agreement with the consideration that a 10% of 
excipient was added and the formulation contained  around 10% of water (as measured by 
TGA). The median volume diameter was equal to 5.41 and 2.78 µm when mannitol and lysine 
were added to the formulation, respectively (Figure 1A). These powders showed a broad 
particle size distribution with a span value of 1.16 and 2.44. The addition of these excipients 
improved the aerodynamic properties compared to the pure HYA powders, decreasing the 
powder entrapped in the device. When stearylamine was added as excipient, the emitted dose 
rose to 88% (Table 1; Figure 1B) and the HYA-stearylamine powder showed the narrowest 
particle size distribution (span 0.59, dv50 2.59 µm). From the respirability data it was 
concluded that there was no direct correlation between the reduction of the hyaluronate 
charge in the solution for spray drying and the powder cohesiveness / aerodynamic behaviour. 
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Among the selected excipients, stearylamine provided the highest respirable fraction, and 
improved the microparticle de-aggregation during aerosolisation. The hyaluronate-
stearylamine (HYA-SteAm) deposition in the fine fraction collector (FFC) reached 45% w/w 
(Figure 1B). This observation can be explained by the lubricant and surfactant properties of 
stearylamine. Stearylamine is a fatty primary amine acting as an emulsifying agent that will 
largely distribute at interfaces between air and water during droplet evaporation (Belotti et al., 
2014; Parlati et al., 2009). This coating with a layer of lubricant results in a lower surface 
energy and lower powder cohesiveness. 
 
3.2  Optimisation of sodium hyaluronate formulations for powder respirability 
Based on the promising effects of stearylamine, other stearyl group-containing surfactants 
(cetostearyl alcohol and stearyl alcohol) were investigated to seek a further improvement of 
the powder performance.  Three different hyaluronate:surfactant ratios (90:10, 95:5 and 99:1) 
were studied for each of these dispersion enhancers. The yield of the production process 
ranged between 44 and 66%, data not shown). 
The in vitro respirability of these powders indicated that a reduction of the amount of 
surfactant in the spray-dried powders afforded a diminution of the emitted dose (Figure 2, 
Table 2). This behaviour was observed with all the three surfactants. The best result in terms 
of respirable fraction was achieved using 5% w/w of the excipient for all the stearyl 
surfactants. This concentration generated microparticles that de-aggregated readily, leading to 
a significantly higher respirable fraction compared to the formulations with 1% surfactant (p< 
0.001 for all formulations). When the excipient was added at 1% w/w, the powders were not 
completely emitted from the device, similarly to the hyaluronate pure spray dried powder 
(HYA).  When the stearyl surfactants were added at 10% w/w, the emitted dose was 
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acceptable (>75 % of the loaded dose) but the powder did not fully de-aggregate and it 
deposited in the induction port and in the coarse fraction collector (CFC) of the impactor (data 
not shown). The lack of linear relationship between surfactant content and in vitro 
respirability can be explained by assuming that at 10% w/w the surfactant concentration (0.92 
mg/ml) is higher than its critical micelle concentration. The latter is reported in literature as 
0.1 mg/ml in water (Wang, 2016). This concentration value is lower to the one employed in 
this study, however it has to be taken into account that the spray drying process was carried 
out in a water-ethanol mixture (70:30 v/v) in which the surfactant CMC is much higher due to 
the higher solubility of the surfactant itself. The micelle formation results in a partial 
internalization of the surfactant during the particle formation process (Parlati et al., 2009).  
Hence, these data suggest that in the spray drying conditions the optimal concentration of 
stearyl surfactant to afford a molecular coating at the particle hyaluronate surface is around 
5% by weight. Although the RF value for the powder containing 10% cetostearyl alcohol was 
not statistically different from that of the powder containing 5% of the same surfactant (p > 
0.05), a similar trend to that obtained with the other surfactants was observed. 
 
SEM images (Figure 3) showed that the spray-dried powders containing the different stearyl 
surfactants exhibited marked differences in morphology. An effect of the surfactant 
concentration on the particle shape was observed as well.  The excipient–free hyaluronate 
powder (containing only HYA) was constituted by particles having spherical shape with some 
concavities and a smooth surface. These samples presented some cohesive particle aggregates 
that account for the aerodynamic assessment observed with FSI (Table 1). Powders with 
stearylamine showed a different shape compared to spray-dried powder of pure HYA. An 
irregular wrinkled shape was produced which was more pronounced as the amount of the 
surfactant in the formulation increased.  Powders containing HYA:cetostearyl alcohol in 
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different ratios had a roundish shape. The particles appeared to be sponge-like with number 
and size of the holes that were proportional to the surfactant concentration. Similar 
morphology was observed when stearyl alcohol was employed in the microparticle 
production.  
To understand the reasons for the different morphology obtained for the amino-moiety 
containing particles compared to the alcoholic moiety containing particles investigations of 
the thermal properties of the particles as well as of the starting materials was carried out.  
Thermo-gravimetric analysis afforded a weight loss of 11.5-13.0% in the 30-140°C 
temperature range irrespective of the type of powder considered.  The DSC traces of the 
starting materials and of the spray dried HYA powders are reported in Figure 4.  Stearylamine 
presented a sharp peak at 57.2°C, followed by a second less pronounced endothermic event 
between 80 and 95°C. While the first peak represents the melting of the material, the second 
one is more difficult to interpret. Most likely it was due to an impurity as the labelled purity 
was 97% w/w. Stearyl alcohol and cetostearyl alcohol presented melting peaks at 60.3 and 
55.9°C, respectively. In both cases the melting peak was preceded by a shoulder of even a 
first. Finally, sodium hyaluronate showed only a very broad endothermic event between 40 
and 140°C which was attributed to moisture evaporation, in agreement with TGA data. 
The powders constituted by HYA and stearylamine (Figure 4 panel b) did not present the 
stearylamine melting peak but only a small endothermic event. This latter tended to appear in 
advance (at lower temperature) as the concentration of the surfactant in the powder decreased. 
This means that the surfactant was present in the powder particles in amorphous form. On the 
contrary, the powders containing HYA, stearyl alcohol (Figure 4 panel c) and cetostearyl 
alcohol (Figure 4 panel d) presented an surfactant melting peak, whose dimension was 
proportional to the surfactant concentration. Interestingly, the DSC traces of these powders 
presented a second small endothermic event that was not observed in the traces of the pure 
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components. This event was around 75°C for the powders containing cetostearyl alcohol and 
78°C for the powder containing stearyl alcohol. The peak temperature was consistently 
observed for the powders having the same components while its intensity was related to the 
surfactant concentration in the sense that the event could be observed only for the powders 
containing 5 and 10% surfactant.  In agreement with data reported in the literature (Albèr et 
al., 2015; Průšová et al., 2013) the second peak was ascribed to the hyaluronan glass 
transition (Tg). In particular Albèr and co-workers (Albèr et al., 2015) reported a Tg of about 
50°C for a polymer of slightly lower molecular weight (17 kDa) while the water moisture 
content was comparable to that observed in the present work; Prusova et al. (Průšová et al., 
2013) provided DSC data affording a Tg ranging from 45.9 and 61.5°C in similar 
experimental conditions for a polymer of 800 kDa. Evidently, the polymer glass transition 
could be observed only in the presence of a certain amount of surfactant.  
The thermal analysis provides a possible explanation for the different particle morphologies 
between the powders containing stearylamine and those containing either stearyl alcohol or 
cetostearyl  alcohol, shown in Figure 3.  Particles containing stearylamine were amorphous in 
nature in particular with respect to the surfactant that constituted the particle shell. Being 
amorphous this shell was likely quite plastic allowing for the particle collapse during the 
solidification, thus leading to the observed corrugated morphology. This behaviour has been 
observed for peptides particles as spray-dried insulin that showed a collapsed and wrinkled 
surface morphology (Balducci et al., 2013). On the other hand, the melting peak of the 
surfactants in the stearyl alcohol- and cetostearyl alcohol-containing particles, suggest that 
these surfactant crystallized between the spray drying inlet and outlet temperatures (90- 
50°C), i.e. in the drying chamber of the spray drier when the boiling and solvent evaporation 
occurred.  The formation of a crystalline shell provided a rigid structure pierced by the 
evaporating solvent bubbles, thus affording the porous sponge-like structure. A similar 
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particle morphology and evaporation mechanism was observed during the formation of BDP 
particles from solution-based pMDI. It is reported that the maximization of evaporation rate 
leads to a rapid escape of the boiling liquid from within the particle giving rise to the 
formation of porous structures with irregular surface geometry (Buttini et al., 2014) (Lewis et 
al., 2014). 
The morphology enabled the aerodynamic behavior observed to be rationalized.  It is reported 
that the shape and presence of the holes on the particle surface (porous particles) reduced the 
effective surface area available for particles contact and cohesion, decrease the density, 
resulting in improved flowability (higher emitted dose) and de-aggregation (higher respirable 
dose). It was concluded that the HYA:surfactant ratio 95:5 afforded the best aerodynamic 
performance.  Thus, spray-dried powders with 5% stearyl surfactant composition were more 
fully characterized with respect to their aerodynamic behavior using the ACI. The data 
generated with the ACI confirmed the results obtained with the FSI demonstrating that the 
presence of a surfactant improve the aerodynamic performance of HA powder; with HA: 
stearylamine (95:5) having the best aerodynamic performance among all the dry powder 
formulations tested (Table 3; Figure -5). 
 
3.3  Biocompatibility of hyaluronate powders with lung cells 
Biocompatibility with human alveolar epithelial cell in vitro was evaluated for the powder 
formulations and their individual constituents using the human alveolar epithelial cell line, 
A549, which is widely used in inhalation toxicology (Zavala et al., 2016). This cell line was 
selected as it is representative of the mucosa at the intended site of action of the HYA 
particles in the peripheral lung. To date, there are no toxicological data available for the 
materials employed in this study when delivered by inhalation. The powder formulations with 
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the highest surfactant concentration (10%) were screened for biocompatibility as they 
possessed the highest potential for toxicity.  The data show that HYA alone did not induce 
overt toxicity after 24 h of exposure (Figure 6A). Although a systematic lowering of the MTT 
assay readout was noted, cell viability remained above 50% of the untreated control at all 
concentrations tested.  For the formulations containing stearyl- surfactants dose dependent 
cytotoxicity was observed (Figure 6B). The effect of individually applied stearyl- surfactants 
on A549 cells ranked similarly to the effect of the formulations containing the same 
surfactants, leading us to conclude that loss of cell viability after exposure to the powders was 
due to the presence of the surfactant component, although somewhat mitigated by co-
administration with HYA in a 10:90 ratio. 
Stearylamine was the most potent of the surfactants in reducing cell viability, LC50 = 1.81 
µg/mL, whereas the least toxic surfactant stearyl alcohol was ten times less potent in terms of 
LC50 (Table 4).  The data show that the relative biocompatibility of formulations was HYA-
stearyl alcohol > HYA-cetostearyl alcohol > HYA-stearylamine, with the surfactants alone 
possessing the same ranking, albeit with lower LC50. 
The LC50 value of excipients approved for inhalation measured using the MTT assay with 
respiratory epithelial cells is typically > 500 mM, with surfactants being more potent, e.g. for 
polysorbates the LC50 value was 0.9-8.0 mM (Scherließ, 2011). For the HYA powder 
containing 5% of stearyl alcohol, the fine particle dose was 1.98 mg from 5 mg of powder 
loaded in a capsule (Table 3). Hence, the stearyl alcohol that potentially reaches the lung can 
be estimated to be approximately 0.1 mg (5% of the 1.98 mg respirable dose).  Although not 
taking into account local concentration gradients during particle dissolution, solubilisation of 
this dose in the available volume of lung lining fluid (20 mL based on estimates of 10-30 mL 
in the conducting airways and 7-20 mL in the alveolar region (Hastedt et al., 2016), would 
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provide a surfactant concentration of around 5 µg/ml, namely 0.018 mM, which compares 
very favorably to an LC50 = 24.7 mg/mL in vitro. Therefore, this data represent a preliminary 
encouraging step toward the gain the FDA approval for this new excipients . Considering the 
need to provide the maximum safety margin, and to balance the findings for biocompatibility 
versus aerosol performance, HYA powders containing 5% stearyl alcohol were determined to 
be the most promising for further studies. 
Conclusions 
A method for engineering respirable hyaluronate powders has been developed using a spray-
drying process.  Particles with a shape and morphology favourable for aerosolization were 
obtained by manipulating the type and concentration of surfactants in the formulation.  Based 
on in vitro evaluations of respirability and biocompatibility, a lead formulation containing 5% 
stearyl alcohol was identified as a highly promising prototype for translating the proposed 
benefits of inhaled hyaluronate into commercially viable, safe and clinically effective 
hyaluronate products. 
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Figure Legends 
Figure 1.  Particle size distribution of spray-dried powders of sodium hyaluronate ± excipients 
(10%).  A. Laser diffraction of hyaluronate powder (HYA, blue) or powders of sodium 
hyaluronate containing lysine (HYA-Lysine, green), mannitol (HYA-Mannitol, red) or 
stearylamine (HYA-stearylamine, black).  B. The deposition of the powders in the fast 
screening impactor, Device = RS01 capsule powder inhaler, IP = induction port, CFC = 
coarse fraction collector, FFC = fine fraction collector (particles < 5 µm; respirable fraction).  
Data represent mean ± standard deviation, n=3. 
 
Figure 2. Respirable fraction measured by fast screening impactor of powders spray dried 
from hyaluronate:stearylamine (HYA-StAm), hyaluronate:cetostearyl alcohol (HYA-
CetSteAlc) and hyaluronate:stearyl alcohol (HYA-SteAlc) in ratio of 99:1, 95:5, 90:10.  Data 
represent mean ± standard deviation, n=3. 
Figure 3. Scanning electron microscopy images of hyaluronate spray-dried powder 
(surfactant-free) and hyaluronate:stearyl surfactants in ratio of 99:1, 95:5, 90:10. Picture 
magnifications are in the range 30-50000 x. 
Figure 4. DSC thermograms of hyaluronate and excipient raw materials (panel a) and spray 
dried powders containing hyaluronate and surfactants in different ratio: 
hyaluronate:stearylamine (HYA-StAm, panel b), hyaluronate:stearyl alcohol (HYA-SteAlc, 
panel c) and hyaluronate:cetostearyl alcohol (HYA-CetSteAlc, panel d). 
Figure 5. Distribution on the stages of an Andersen cascade impactor of the 
hyaluronate:surfactant 95:5 spray-dried powders: HYA:stearylamine (HYA-StAm-5), 
HYA:stearyl alcohol (HYA-SteAlc-5) and HYA:cetostearyl alcohol (HYA-CetSteAlc-5). 
D&C = device and capsule, IP = induction port, S1-6 =stages 1 to 6, F = filter. Powders were 
aerosolised using an RS01 capsule powder inhaler device (loaded dose 5 mg). Data represent 
mean ± standard deviation, n=3. 
Figure 6. Biocompatibility of sodium hyaluronate and surfactants alone and in the spray dried 
powders with A549 alveolar epithelial cells evaluated using an MTT assay for cell 
viability.  A. Stearyl surfactants or hyaluronate (HYA) applied as single agents. B.  
hyaluronate:surfactant 90:10 spray-dried powders. Powders were applied in solution to 
A549 cells for 24 h, data represent mean ± SD (n=18; three independent experiments with 
6 replicates at each concentration). 
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Tables 
 
 
Table 1.  Hyaluronate formulations screened to identify excipients that enhance spray drying yield, emitted dose and respirable fraction. Data 
represent mean ± standard deviation, n=3. 
 
 Feed solution to spray drying  Powder characterization 
Hyaluronate 
powder 
formulation 
Surfactant 
type 
Surfactant 
ratio to 
hyaluronate 
(% w/w) 
Solute content 
of feed 
suspension 
(% w/v) 
Surfactant 
concentration 
(mg/ml) 
Production 
yield 
(%) 
HYA 
content 
(%) 
Emitted 
dose 
(%) 
Respirable 
fraction 
(%) 
Hyaluronate 
(HYA) 
- - 0.83 - 67.9 ± 2.1 91.1 ± 0.5 38.6 ± 0.10 25.4 ± 3.7 
HYA-Mannitol Mannitol 10 0.92 0.92 65.0 ± 3.2 80.6 ± 0.8 67.4 ± 0.11 27.6 ± 0.6 
HYA-Lysine Lysine 10 0.92 0.92 76.7 ± 1.4 79.8 ± 0.8 58.7 ± 0.05 30.9 ± 5.2 
HYA-
Stearylamine 
Stearylamine 10 0.92 0.92 49.0 ± 2.4 78.9 ± 2.0 88.1 ± 0.01 45.0 ± 4.1 
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Table 2. Optimisation of hyaluronate:stearyl surfactant ratio by evaluation of spray dry production yield and inhalation performance. 
Composition of the feed solution to spray drying is reported A loaded dose of 5 mg powder in a capsule inhaler device RS01 was evaluated 
using the fast screening impactor at 60 L/min to measure emitted dose and respirable fraction of the spray-dried hyaluronate powders.  Data 
represent mean ± standard deviation, n=3. 
 
 Feed solution to spray drying Powder characterization 
Hyaluronate 
powder 
formulation 
Stearyl 
surfactant 
Surfactant 
ratio to 
hyaluronate 
(% w/w) 
Solute 
content 
(% w/v) 
Surfactant 
concentration 
(mg/ml) 
Hyaluronate 
content 
(%) 
Emitted dose 
(%) 
Respirable 
fraction 
(%) 
HYA-StAm-1  1 0.84 0.084 88.1 ± 0.9 58.2 ± 0.20 27.0 ± 1.7 
HYA-StAm-5 Stearylamine 5 0.88 0.44 83.2 ± 0.4 80.1 ± 0.29 51.2 ± 2.0 
HYA-StAm-10  10 0.92 0.92 78.3 ± 1.9 88.1 ± 0.01 45.0 ± 4.1 
HYA-CetSteAlc-1  1 0.84 0.084 90.1 ± 1.2 71.8 ± 0.08 27.2 ± 1.1 
HYA-CetSteAlc-5 
Cetostearyl 
alcohol 
5 0.88 0.44 86.4 ± 1.7 76.1 ± 0.14 36.2 ± 1.7 
HYA-CetSteAlc-10  10 0.92 0.92 79.2 ± 0.7 91.5 ± 0.01 34.8 ± 3.6 
HYA-SteAlc-1  1 0.84 0.084 89.4 ± 1.2 69.1 ± 0.07 30.0 ± 7.0 
HYA-SteAlc-5 Stearyl alcohol 5 0.88 0.44 85.4 ± 1.5 75.9 ± 0.01 38.4 ± 0.1 
HYA-SteAlc-10  10 0.92 0.92 79.6 ± 1.1 90.4 ± 0.05 31.6 ± 0.7 
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Table 3.  Characterisation of the aerosol properties of the powders with the excipient ratio 
resulting in the highest respirable fraction (hyaluronate:stearyl surfactant ratio 95:5).  Powders 
(5 mg) were aerosolised using an RS01 capsule powder inhaler device and deposition was 
measured in an Andersen impactor operated at 60 L/min. ED = emitted dose, MMAD = mass 
median aerodynamic diameter, FPD = fine particle dose, FPF = fine particle dose, RF = 
respirable fraction. Data represent mean ± standard deviation, n=3. 
 
Hyaluronate 
powder formulation 
ED 
(%) 
MMAD 
(µm) 
FPD 
(mg) 
FPF 
(%) 
RF 
(%) 
HYA-StAm-5 79.9 ± 0.5 1.96 ± 0.12 2.20 ± 0.21 66.3 ± 5.6 49.4 ± 3.5 
HYA-CetSteAlc-5 72.5 ± 1.7 2.28 ± 0.36 1.80 ± 0.08 59.0 ± 2.5 38.6 ± 2.1 
HYA-SteAlc-5 73.2 ± 1.9 2.03 ± 0.13 1.98 ± 0.05 64.0 ± 0.6 43.8 ± 0.9 
 FPF = FPD/amount collected in the impactor 
 RF= FPD/loaded dose 
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Table 4.  Comparison of LC50 (50% of the lethal concentration) for stearyl surfactants alone 
or in combination (10:90 ratio) with sodium hyaluronate. The agents were applied to human 
alveolar epithelial cells in solution for 24 h. The data represent the mean and the 95% 
confidence interval (CI) of n=3 individual experiments. 
 
 
 
Stearyl surfactant / powder 
formulation compositions 
LC50 (95% CI) 
(µg/ml of surfactant) 
HYA-StAm-10 3.85 (3.09-4.79) 
Stearylamine 1.81 (1.51-2.18) 
HYA-CetSteAlc-10 15.59 (14.42-16.86) 
Cetostearyl alcohol 13.18 (11.53-15.06) 
HYA-SteAlc-10 19.42 (17.17-21.97) 
Stearyl alcohol 24.65 (18.37-33.07) 
 
 
